AR and prostate cancer: Knockdown of SRD5A3 in prostate cancer cells contributed to a dominant decrease in DHT production and a significant reduction in cell viability, suggesting a role in maintenance of androgen–androgen receptor-pathway activity in CRPC cells and the enzymatic activity might be a potential target for therapy of CRPC (126).